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1. Introduction 
Cytomegalovirus (CMV) is a member of the Herpesviridae  family and is characterized 
by a lifelong latency in the host (1). Clinical presentations of CMV infection are mainly minimal 
to absent in immunocompetent hosts but can lead to severe symptoms up to life-threatening 5 
conditions in immunosuppressed patients.  
Prophylactic or preemptive therapy against CMV infection has successfully reduced the 
incidence of CMV disease in transplant recipients (2). However, it still remains one of the major 
infectious complications and causes of morbidity and mortality after hematopoietic stem cell 
transplantation (HSCT) (1, 3). Risk factors for CMV infection in HSCT patients include CMV 10 
seropositivity of donor and recipient, allogeneic transplantation (especially with T cell-depleted 
unrelated or HLA-mismatched donors) and cell source.  Cord blood recipients have both longer 
and higher cumulative incidences of CMV infection compared to peripheral blood or allogeneic 
bone marrow recipients from related or unrelated donor origin (4-6). In HSCT patients, cellular 
immunity is mainly significantly impaired during the first 100 days post-transplant. CMV infection 15 
in HSCT patients manifests as enterocolitis, pneumonia, hepatitis or as retinitis and bone 
marrow suppression (1). Although less frequently, late CMV reactivation (> 100 days 
posttransplant) can occur (7, 8).  
The number of available drugs for treatment of CMV infection is limited. Ganciclovir, the 
mainstay treatment of CMV infection, is a nucleoside analog that inhibits the viral DNA 20 
polymerase. It is first phosphorylated to its monophosphate form by the CMV-encoded UL97 
protein kinase and further converted by cellular kinases to the triphosphate form, which is the 
active metabolite.  Ganciclovir-triphosphate competitively inhibits the binding of deoxyguanosine 
triphosphate to the viral DNA polymerase finally resulting in inhibition of viral DNA synthesis (9). 
Ganciclovir remains the first-line agent for CMV prophylaxis and preemptive therapy reducing 25 
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the risk of CMV infection and disease compared to placebo (3). A major adverse effect related 
to its use is hematologic toxicity. 
Other antiviral agents such as foscarnet and cidofovir, also inhibit the CMV DNA 
polymerase but have the ability to inhibit UL97 protein kinase mutants of CMV because cidofovir 
is independent of this kinase for activation and foscarnet does not require activation to inhibit 5 
the viral DNA polymerase (9). Their use is limited due to toxicity, more specifically to mineral 
and electrolyte abnormalities as a result of renal impairment (foscarnet) and renal toxicity 
associated with cidofovir. This underscores the importance of adequate hydration and frequent 
monitoring of serum creatinine levels in patients receiving foscarnet or cidofovir (9). 
Resistance of CMV to ganciclovir is mostly caused by mutations within the UL97 gene 10 
and less frequently by alterations within the viral UL54 DNA polymerase gene (UL54 gene) 
(10,11). Resistance to cidofovir and foscarnet is linked to mutations in the viral DNA polymerase 
gene. In general, mutations conferring resistance to both cidofovir and ganciclovir are located in 
the exonuclease domain and region V of the viral DNA polymerase, whereas those conferring 
foscarnet resistance map between regions II and III of the viral enzyme. Some mutations in and 15 
near region III confer dual foscarnet and ganciclovir resistance, and a few mutations (such as 
A834P and deletion 981-2) confer resistance to the three anti-CMV drugs. Emergence of 
cidofovir resistance appears to be an extremely rare event and it arises in the clinic following 
sustained ganciclovir administration (10,11).  
A few reports have highlighted the importance of CMV resistance in pediatric HSCT 20 
populations.  CMV-infected infants after HSCT were found to develop ganciclovir resistance 
associated with UL97 (12-15). However, in some cases, multiple UL97 and UL54 (DNA 
polymerase) mutations that conferred resistance to ganciclovir and foscarnet (16) or to all three 
currently available anti-CMV drugs (i.e. ganciclovir, cidofovir and foscarnet) have been 
described (17-19).   25 
We report a case of fatal CMV infection in a young patient with primary immunodeficiency 
and consecutive HSCT who developed first ganciclovir resistance (due to a mutation in the UL97 
4 
 
protein kinase) and later on multidrug-resistant CMV disease associated with a single mutation 
in the DNA polymerase. 
2. Materials and methods 
2.1. Case  
A 4-month old girl (weight 5.8 kg) was referred for fever, failure to thrive and bloody 5 
diarrhea. She was the first child of consanguineous parents, so severe immunodeficiency was 
presumed. CMV was detected in the blood with a viral load of 3.77 10E6 copies/ml, treatment 
with ganciclovir (5 mg/kg, twice daily) was started.  MHC class II deficiency was diagnosed 
and the search for a stem cell donor was initiated. Four weeks later the dose frequency was 
reduced to a once daily administration. However, 1 week later, the CMV viral load started to 10 
increase and therapy with ganciclovir was switched from once daily again to twice daily 
administration (double dose, based on the most recent body weight). As the CMV viral load 
still increased, ganciclovir administration was stopped and therapy was switched to foscarnet. 
No HLA identical donor nor cord blood was found so haploidentical HSCT was planned.  For 
more than one month, the patient received foscarnet (2 x 350mg) and simultaneously CMV-15 
specific immunoglobulins . Antiviral resistance testing in a blood sample (RV-511) was 
performed and revealed the presence of a mixed population of M460V-mutant and wild-type 
virus in the UL97 protein kinase. This UL97 mutation is known to confer resistance to 
ganciclovir with susceptibility to foscarnet and cidofovir (11). Results on genotyping testing of 
samples recovered from blood, cerebrospinal fluid (CSF) or nasopharyngeal aspirate (NPA) 20 
are presented in Table 1.  
Despite antiviral treatment the patient deteriorated and developed CMV encephalitis 
confirmed by positivity of CMV PCR on CSF taken on day -14 (RV-517), which showed a 
similar resistance profile as the blood samples (RV-511 and RV-516) and the NPA (RV-910), 
taken during the same time period. Retrospective analysis of NPA samples (RV-905 to RV-25 
910) recovered before indicated that ganciclovir-resistance emerged at the moment that the 
patient developed encephalitis. 
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An allogeneic transplantation with peripheral blood stem cells from a haploidentical donor 
was performed, after selection of CD34 cells from the graft. Both the donor and receptor were 
CMV IgG seropositive. The conditioning regimen consisted of intravenous busulfan 
(16x1mg/kg) and fludarabine (4x35mg/m²). Three days after HSCT, the patient developed 
fever for which antibiotics were started. Because of progression of neurologic encephalitic 5 
disturbances suggestive of central CMV infection, prophylactic anti-epileptics were started 
(phenobarbital) and cidofovir was added empirically to the foscarnet antiviral treatment. 
Antiviral resistance testing of a blood sample on day +1 (RV-520) showed, in addition to a 
mixed population of M460V-mutant and wild-type virus at the UL97 protein kinase, also the 
presence of a mixed population of 981-982 deletion mutant and wild-type virus in the DNA 10 
polymerase. This is known to confer resistance to ganciclovir, foscarnet and cidofovir (11). The 
same viral populations were detected at the same time in the NPA (RV-911)  on  day +8.  (RV-
521).  
On day +19, the UL97 M460V-mutant population was not identified anymore in the blood 
(RV-523) but a mixed population of DNA polymerase mutant virus bearing the 981-982 deletion 15 
was present. In only 3 days, the mutant virus totally replaced the wild-type virus as the RV-525 
CMV-positive clinical sample and presented a pure population of DNA polymerase mutant 
virus with the 981-982 deletion (11). Thirteen days after HSCT, the patient was referred to the 
intensive care unit because of exacerbation of respiratory problems. Cidofovir was stopped 
because of severe cytopenia and increase of the CMV viral load. During the following days 20 
there was a further clinical deterioration of respiratory and liver function and uncontrollable 
sepsis. It was decided to stop antiviral treatment and to start palliative care. The presence of 
multidrug-resistant CMV infection [due to the presence of the 981-982 deletion in the viral DNA 
polymerase not only in the blood (RV-526, RV-528, and RV-527) but also in urine (RV-524 
and RV-913) and NPA (RV-912)] together with encephalitis, were all cumulating in a 25 
respiratory arrest with cardiac arrest and death of the patient at day +36. A schematic 
representation of the evolution of the CMV viral load and of the administration of anti-CMV 
therapy is presented in Figure 1. 
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2.2. CMV viral load determination  
Throughout the patient’s treatment, CMV DNA monitoring was performed with 
quantitative CMV PCR.  CMV PCR was performed following an in-house method based on 
real-time technology with continuous TaqMan-probe detection according to previously 5 
published protocol (20). The detection treshold was set at 300 copies/mL. Nucleic acid 
extraction was performed from whole blood following generic protocol on 
NucliSENS®easyMag® (bioMerieux, Marcy-l’Etoile, France). Consecutive amplification and 
detection was performed using CFX96 Real-Time PCR Detection System (Bio-Rad 
Laboratories, Nazareth Eke, Belgium). 10 
 
2.3. Antiviral resistance for CMV  
Testing of CMV drug-resistance in the different isolates was performed by genotyping 
the UL97 protein kinase responsible for ganciclovir phosphorylation and the UL54 (viral DNA 
polymerase), as detailed in the RegaVir project (website: regavir.org). The DNA from the 15 
different clinical samples was first extracted with a QIAamp bloodkit (Qiagen) according to the 
manufacturer's instructions. The entire CMV UL54 and UL97 genes were amplified using 
FastStart high-fidelity DNA polymerase (Roche Applied Science). The polymerase chain 
reaction products were purified with a QIAquick Purification Kit (Qiagen), and gene amplicons 
were directly sequenced using the cycle sequencing BigDye Terminator kit, version 3.1, on an 20 
ABI 3730 sequencing system (Applied Biosystems) and a set of primers spanning the entire 
coding regions of the genes. The sequencing results were computer assembled and compared 
with the UL97 protein kinase and DNA polymerase sequences from the reference AD-169 
CMV strain (Genbank accession number of the reference sequence AD169 is X17403) using 
the software SeqScape, version 2.7 (Applied Biosystems). The presence of the mutations was 25 
confirmed by two independent sequencing reactions using both forward and reverse primers.  
 
3. Discussion 
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Ganciclovir has been the mainstay antiviral drug for CMV treatment for many years. However, 
an increasing number of ganciclovir-resistant CMV infections has been reported in solid organ 
and especially pediatric bone marrow transplant recipients (11,21). Here we report a case of 
multidrug-resistant CMV infection in a severely immunocompromised pediatric patient. CMV 
encephalitis as a rare complication after HSCT was in our patient associated with recurrent 5 
CMV viremia following prolonged administration of ganciclovir and foscarnet and emergence 
of drug-resistance. The development of CMV central nervous system disease in HSCT-
patients is associated with several risk factors, including, among others, drug-resistance and 
high mortality despite therapy with a combination of anti-CMV drugs (ganciclovir, foscarnet and 
cidofovir) (22). Suboptimal ganciclovir dose may promote the emergence of drug-resistance 10 
since adequate drug levels are crucial to control viral replication. High drug levels are known 
to delay or prevent development of resistance while suboptimal drug doses encourage viral 
replication and emergence of drug-resistance.  
 In contrast to the present case-report representing infection by the same CMV strain in 
different body compartments, a case of temporal and spatial compartmentalization of drug-15 
resistant cytomegalovirus (CMV) in a child with CMV meningoencephalitis has been described 
by Frange et al (23). 
Rapid availability of CMV viral load measurements as well as sensitive detection of 
CMV in CSF are crucial for adequate antiviral chemotherapy (24). If resistance is suspected 
based on the persistently rising viral load, its accurate assessment by genotypic testing is 20 
mandatory (25). In the presented case report, close monitoring of genotypic resistance gave 
an opportunity to modulate the antiviral treatment in function of the identified mutant viruses. 
In our severely immunocompromised pediatric patient under antiviral drug pressure, a mixed 
population of wild-type and mutant virus bearing a point mutation in the UL97 protein kinase 
(M460V) was first detected in different body compartments (CSF, NPA and blood). This UL97 25 
amino acid change is known to be associated with resistance to ganciclovir. After a short 
period, a new viral mutant harboring the DNA polymerase 981-982 deletion in the DNA 
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polymerase was detected in addition to the UL97 mutant virus, both in the blood and NPA. 
Importantly, this DNA polymerase deletion has been linked to multiple drug-resistance 
(ganciclovir, cidofovir and foscarnet). The DNA polymerase 981-982 deletion mutant appeared 
to emerge following foscarnet therapy in our patient (Figure 1). Two weeks later, the presence 
of a pure mutant viral population with the deletion in UL54 was identified in the blood. Notably, 5 
the virus with the DNA polymerase deletion was later on detected not only in blood but also in 
urine and NPA, indicating a generalized multidrug-resistance CMV infection. At this point, no 
approved therapeutic options for CMV disease were available and unfortunately, no access to 
compassionate use of novel anti-CMV drugs under clinical development was available. 
Although a few reports have described the use of leflunomide for therapy of multidrug-10 
resistance CMV disease (26-29), treatment with this drug having both immunosuppressive and 
anti-CMV properties was not envisaged in our patient.  
Although new molecules (i.e. maribavir, letermovir, brincidofovir) are studied in 
ongoing clinical trials (www.clinicaltrials.gov (30)), this case report indicates the urgent need 
for the development and market availability of new anti-CMV drugs. Although additional data 15 
are required, there might be role for artesunate in the treatment of mild CMV disease due to 
multidrug-resistant CMV strains (31). 
Rapid modern molecular diagnostic approaches are essential for detection of CMV 
resistance as a guidance for treatment of transplant recipients at high risk for drug-resistance 
CMV disease.  20 
 
References 
 
 (1)  Russell MY, Palmer A, Michaels MG. Cytomegalovirus infection in pediatric immunocompromised 
hosts. Infect Disord Drug Targets 2011;11:437-48. 25 
 (2)  Bordon V, Bravo S, Van RL, de MB, Benoit Y, Laureys G, et al. Surveillance of cytomegalovirus (CMV) 
DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection 
and disease. Transpl Infect Dis 2008;10:19-23. 
9 
 
 (3)  Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. 
Hematol Oncol Clin North Am 2011;25:151-69. 
 (4)  Keever-Taylor CA, Bredeson C, Loberiza FR, Casper JT, Lawton C, Rizzo D, et al. Analysis of risk factors 
for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO 
incompatibility, and method of T-cell depletion. Biol Blood Marrow Transplant 2001;7:620-30. 5 
 (5)  Yoon HS, Lee JH, Choi ES, Seo JJ, Moon HN, Kim MN, et al. Cytomegalovirus infection in children who 
underwent hematopoietic stem cell transplantation at a single center: a retrospective study of the 
risk factors. Pediatr Transplant 2009;13:898-905. 
 (6)  Yi ES, Kim YJ. Cytomegalovirus infection according to cell source after hematopoietic cell 
transplantation in pediatric patients. Yonsei Med J 2012;53:393-400. 10 
 (7)  Cervera C, Pineda M, Linares L, Marcos MA, Esteva C, Anton A, et al. Impact of valganciclovir 
prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ 
transplant recipients. Transplant Proc 2007;39:2228-30. 
(8)   Sousa H, Boutolleau D, Ribeiro J, Teixeira AL, Pinho Vaz C, Campilho F, Branca R, Campos A Jr, 
Baldaque I, Medeiros R. Cytomegalovirus infection in patients who underwent allogeneic 15 
hematopoietic stem cell transplantation in Portugal: a five-year retrospective review. Biol Blood 
Marrow Transplant. 2014 Dec;20(12):1958-67.  
 
 (9)  Biron KK. Antiviral drugs for cytomegalovirus diseases. Antiviral Res 2006;71:154-63. 
 (10)  Gilbert C, Boivin G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents 20 
Chemother 2005;49:873-83. 
 (11)  Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 
2010;23:689-712. 
 (12)  Ohta H, Matsuda Y, Tokimasa S, Sawada A, Kim JY, Sashihara J, et al. Foscarnet therapy for ganciclovir-
resistant cytomegalovirus retinitis after stem cell transplantation: effective monitoring of CMV 25 
infection by quantitative analysis of CMV mRNA. Bone Marrow Transplant 2001;27:1141-5. 
 (13)  Gohring K, Feuchtinger T, Mikeler E, Lang P, Jahn G, Handgretinger R, et al. Dynamics of the 
emergence of a human cytomegalovirus UL97 mutant strain conferring ganciclovir resistance in a 
pediatric stem-cell transplant recipient. J Mol Diagn 2009;11:364-8. 
 (14)  Kim YJ, Boeckh M, Cook L, Stempel H, Jerome KR, Boucek R, Jr., et al. Cytomegalovirus infection and 30 
ganciclovir resistance caused by UL97 mutations in pediatric transplant recipients. Transpl Infect Dis 
2012;14:611-7. 
 (15)  Erice A, Chou S, Biron KK, Stanat SC, Balfour HH, Jr., Jordan MC. Progressive disease due to 
ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 1989;320:289-
93. 35 
 (16)  Choi SH, Hwang JY, Park KS, Kim Y, Lee SH, Yoo KH, et al. The impact of drug-resistant cytomegalovirus 
in pediatric allogeneic hematopoietic cell transplant recipients: a prospective monitoring of UL97 and 
UL54 gene mutations. Transpl Infect Dis 2014;16:919-29. 
10 
 
 (17)  Blackman SC, Lurain NS, Witte DP, Filipovich AH, Groen P, Schleiss MR. Emergence and 
compartmentalization of fatal multi-drug-resistant cytomegalovirus infection in a patient with 
autosomal-recessive severe combined immune deficiency. J Pediatr Hematol Oncol 2004;26:601-5. 
 (18)  Drouot E, Piret J, Lebel MH, Boivin G. Characterization of multiple cytomegalovirus drug resistance 
mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping. 5 
J Clin Microbiol 2014;52:4043-6. 
 (19)  Springer KL, Chou S, Li S, Giller RH, Quinones R, Shira JE, et al. How evolution of mutations conferring 
drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected 
hematopoietic cell transplant recipients. J Clin Microbiol 2005;43:208-13. 
 (20)  Vanpoucke H, Van Vlem B, Vanholder R, Van Renterghem L. Significance of qualitative polymerase 10 
chain reaction combined with quantitation of viral load in the diagnosis and follow-up of 
cytomegalovirus infection after solid-organ transplantation. Intervirology 1999;42:398-404. 
 (21)  Strasfeld L, Chou S. Antiviral drug resistance: mechanisms and clinical implications. Infect Dis Clin 
North Am 2010;24:809-33. 
 (22)  Reddy SM, Winston DJ, Territo MC, Schiller GJ. CMV central nervous system disease in stem-cell 15 
transplant recipients: an increasing complication of drug-resistant CMV infection and protracted 
immunodeficiency. Bone Marrow Transplant 2010;45:979-84. 
(23) Frange P, Boutolleau D, Leruez-Ville M, Touzot F, et al. Temporal and spatial compartmentalization of 
drug-resistant cytomegalovirus (CMV) in a child with CMV meningoencephalitis: implications for 
sampling in molecular diagnosis. J Clin Microbiol. 2013 Dec;51(12):4266-9.  20 
(24) Boeckh M. Complications, diagnosis, management, and prevention of CMV infections: current and 
future. Hematology Am Soc Hematol Educ Program 2011;2011:305-9. 
 (25)  Boeckh M, Murphy WJ, Peggs KS. Reprint of: Recent advances in cytomegalovirus: an update on 
pharmacologic and cellular therapies. Biol Blood Marrow Transplant 2015;21:S19-S24. 
 (26)  Avery RK, Bolwell BJ, Yen-Lieberman B, Lurain N, Waldman WJ, Longworth DL, et al. Use of 25 
leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus 
infection. Bone Marrow Transplant 2004;34:1071-5. 
 (27)  Levi ME, Mandava N, Chan LK, Weinberg A, Olson JL. Treatment of multidrug-resistant 
cytomegalovirus retinitis with systemically administered leflunomide. Transpl Infect Dis 2006;8:38-
43. 30 
 (28)  Verkaik NJ, Hoek RA, van BH, van Hal PT, Schipper ME, Pas SD, et al. Leflunomide as part of the 
treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report 
and review of the literature. Transpl Infect Dis 2013;15:E243-E249. 
 (29)  Dunn JH, Weinberg A, Chan LK, Mandava N, Levi ME, Olson JL. Long-term suppression of multidrug-
resistant cytomegalovirus retinitis with systemically administered leflunomide. JAMA Ophthalmol 35 
2013;131:958-60. 
(30) Sellar RS, Peggs KS. Management of multidrug-resistant viruses in the immunocompromised host. Br J 
Haematol 2012;156:559-72. 
 
11 
 
 
(31) Germi R, Mariette C, Alain S, Lupo J, Thiebaut A et al. Success and failure of artesunate treatment in five 
transplant recipients with disease caused by drug-resistant cytomegalovirus. Antiviral Res. 2014 
Jan;101:57-61.. 
 5 
 
Acknowledgements 
Financial disclosure: no conflicts of interest or financial support exist. 
 
Author’s contributions 10 
Concept/design: T. Bauters, V. Bordon, E. Padalko 
Data acquisition/analysis/interpretation and manuscript revision: T. Bauters, V. Bordon, L. 
Florin, E. Padalko, R. Snoeck, G. Andrei, S. Gillemot, P. Fiten, G. Opdenakker, G. Laureys  
Drafting article: T. Bauters, V. Bordon, E. Padalko, G. Andrei, R. Snoeck  
Approval of article: all authors 15 
 
Table 1: Overview of amino acids changes in UL97 and UL54 with resistance profiles 
Day Samples 
(RegaVir 
code) 
CMV DNA1  Type of 
sample 
Amino acids changes 
related to resistance in: 
Resistance to: Amino acid changes related to 
genetic polymorphisms 
UL97 (protein 
kinase)  
UL54 (DNA 
polymerase) 
UL97 (protein 
kinase) 
UL54 
(DNA 
polymeras
e) 
-82 Not 
available 
3,77 x 10e6 Blood Not available Not 
available 
Not available Not available Not 
available 
-79 RV-905 Positive NPA None None None None 4 
-72 RV-906 Positive NPA None None None None 4 
-65 RV-907 Positive NPA None None None None 4 
12 
 
-43 RV-908 Positive NPA None None None None 4 
-37 RV-909 DL NPA NA NA - NA NA 
-19 RV-910 Positive NPA M460V 2 None GCV None 4 
-16 RV-511 1,34 x 10e5 Blood M460V 2 none GCV None 4 
-14 RV-517 Positive CSF M460V 2 none GCV None 4 
-9 RV-516 1,44 x 10e5 Blood M460V 2 none GCV None 4 
+1 RV-520 5,98 x 10e5 Blood M460V 2 981-982 
del.3 
GCV, CDV, FOS None 4 
+5 RV-911 Positive NPA M460V 2 981-982 
del. 3 
GCV, CDV, FOS None 4 
+8 RV-521 5,52 x 10e6 Blood M460V 2 981-982 
del. 3 
GCV, CDV, FOS N68D, I244V 4 
+19 RV-523 1,06 x 10e7 Blood none 981-982 
del. 3 
GCV, CDV, FOS None 4 
+22 RV-525 1,65 x 10e6 Blood none 981-982 
del. 3 
GCV, CDV, FOS None 4 
+26 RV-526 5,94 x 10e7 Blood none 981-982 
del. 3 
GCV, CDV, FOS None 4 
+28 RV-524 Positive Urine none 981-982 
del. 3 
GCV, CDV, FOS None 4 
+29 RV-528 5,09 x 10e7 Blood none 981-982 
del. 3 
GCV, CDV, FOS None 4 
+30 RV-913 Positive Urine none 981-982 
del. 3 
GCV, CDV,FOS None 4 
+31 RV-912 ND NPA none 981-982 
del. 3 
GCV, CDV, FOS None 4 
+33 RV-527 1,29 x 10e8 Blood none 981-982 
del. 3 
GCV, CDV, FOS None 4 
 
Abbreviations: NA (not amplifiable), NPA (nasopharyngeal aspirate), CSF (cerebrospinal fluid), GCV (ganciclovir), CDV 
(cidofovir), FOS (foscarnet), del (deletion), DL (detection limit), ND (not detected). 1 CMV DNA viral load (copies/ml) 
for blood or qualitative result for other specimen types; 2 mixed population of wild-type and mutant virus;  3 pure 
population of mutant virus. 4 amino acid changes in S655L, F669L, N685S, A885T and N898D.  5 
Samples marked in bold were analyzed when they were recovered from the patient in order to adapt antiviral 
treatment while those indicated in italic were evaluated retrospectively. 
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Figure 1. Overview of CMV-DNA PCR in relation to time, anti-CMV therapy and samples genotypically analyzed. 
 
      Wild-type;      Ganciclovir resistance;       Ganciclovir, cidofovir, foscarnet resistance;  not amplifiable.  
Abbreviations: NPA (nasopharyngeal aspirate), CSF (cerebrospinal fluid) 
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